Seronegative antibody-mediated neurology after immune checkpoint inhibitors

Annals of Clinical and Translational Neurology
Robert WilsonSarosh R Irani

Abstract

Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune-related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody-mediated neurological diseases after checkpoint inhibitors: longitudinally extensive transverse myelitis, Guillain-Barré syndrome, and myasthenia gravis. All patients shared three characteristics: symptoms commenced 4 weeks after drug administration, responses to conventional immunotherapies were excellent, and autoantibodies traditionally associated with their syndrome were absent. However, serum immunoglobulins from the myelitis and Guillain-Barré syndrome patients showed novel patterns of tissue reactivity. Vigilance is required for antibody-mediated neurology after checkpoint inhibitor administration. This phenomenon may inform the immunobiology of antibody-mediated diseases.

References

Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Mar 15, 2013·Practical Neurology·Ilja BotDieta Brandsma
May 24, 2014·Annals of Neurology·Liane DahmHannelore Ehrenreich
Apr 27, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Patrick WatersRomain Marignier
Jun 29, 2016·Annals of Neurology·Lisa Ann GerdesReinhard Hohlfeld
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Jan 10, 2017·Expert Opinion on Biological Therapy·Tawee TanvetyanonScott J Antonia
Mar 24, 2017·Brain : a Journal of Neurology·Alex J ClarkDavid L H Bennett
May 17, 2017·Journal of Neuromuscular Diseases·Dana S CooperRabia Malik
Aug 20, 2017·Neurology·Shigeaki SuzukiMakoto Matsui
Nov 7, 2017·Nature Reviews. Neurology·Lidia M YshiiRoland S Liblau
Jan 9, 2018·The Journal of Clinical Investigation·Rituparna DasKavita M Dhodapkar

❮ Previous
Next ❯

Citations

Apr 19, 2020·Practical Neurology·Shane LyonsTimothy J Counihan
Apr 22, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Alberto VogrigJerome Honnorat
Sep 8, 2020·Asia-Pacific Journal of Clinical Oncology·Siyuan FanHongzhi Guan
Sep 11, 2020·Case Reports in Oncological Medicine·M L VickersR Chew
Jun 10, 2020·Current Neurology and Neuroscience Reports·Rebecca A HarrisonJohn de Groot
May 28, 2019·Frontiers in Immunology·Iris LavonAdi Vaknin-Dembinsky
Nov 12, 2020·Eye and Brain·Caberry W YuJonathan A Micieli
Dec 5, 2020·Neurology. Neuroimmunology and Neuroinflammation·Simon RinaldiUNKNOWN Australian and New Zealand MOG Study Group
Nov 15, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Elia Sechi, Anastasia Zekeridou
Mar 2, 2021·Seminars in Ophthalmology·Loulwah Mukharesh, Bart K Chwalisz
Apr 5, 2021·Journal of the Neurological Sciences·Cecilia Zivelonghi, Anastasia Zekeridou
Mar 4, 2021·Neurology·Alessandro MariniAlberto Vogrig
Mar 25, 2021·Journal of Immunotherapy·Jorien B E JanssenHarm Westdorp

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.